CYP17A1

cytochrome P450 family 17 subfamily A member 1, the group of Cytochrome P450 family 17

Basic information

Region (hg38): 10:102830531-102837472

Previous symbols: [ "CYP17" ]

Links

ENSG00000148795NCBI:1586OMIM:609300HGNC:2593Uniprot:P05093AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • congenital adrenal hyperplasia due to 17-alpha-hydroxylase deficiency (Supportive), mode of inheritance: AR
  • 46,XY disorder of sex development due to isolated 17,20-lyase deficiency (Supportive), mode of inheritance: AR
  • congenital adrenal hyperplasia due to 17-alpha-hydroxylase deficiency (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Adrenal hyperplasia, congenital, due to 17-alpha-hydroxylase deficiencyAREndocrine; Genitourinary; OncologicIndividuals may not necessarily manifest with adrenal crisis, but mineralocorticoid excess may result in severe hypokalaemic hypertension, and awareness may allow preventive measures and treatment (eg, including glucocorticoids and mineralcorticoid antagonists); Treatment of genitourinary anomalies, as well as related hypogonadotrophic hypogonadism (eg, with hormone replacement therapy, as well as surgery in some individuals), can be beneficial; Due to risk of malignancy, gonadectomy may be indicated in genotypic malesEndocrine;Genitourinary; Oncologic4288776; 6039879; 4303304; 5456802; 999330; 6976525; 2843762; 2026124; 1648117; 2808364; 7629254; 8855840; 9360545; 9326943; 9177409; 11549685; 14671162; 16121340; 18559916; 20170344; 21823532; 22452398; 21550081; 22954317

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the CYP17A1 gene.

  • not provided (58 variants)
  • Deficiency of steroid 17-alpha-monooxygenase (30 variants)
  • 17-alpha-hydroxylase/17,20-lyase deficiency, combined complete (8 variants)
  • Congenital adrenal hyperplasia (4 variants)
  • CYP17A1-related disorder (3 variants)
  • 17,20-lyase deficiency, isolated (1 variants)
  • 17-alpha-hydroxylase/17,20-lyase deficiency, combined partial (1 variants)
  • Breast cancer, susceptibility to (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the CYP17A1 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
188
clinvar
2
clinvar
191
missense
16
clinvar
27
clinvar
49
clinvar
2
clinvar
94
nonsense
20
clinvar
4
clinvar
24
start loss
3
clinvar
3
frameshift
20
clinvar
15
clinvar
35
inframe indel
2
clinvar
3
clinvar
5
splice donor/acceptor (+/-2bp)
5
clinvar
7
clinvar
12
splice region
1
20
21
non coding
1
clinvar
7
clinvar
76
clinvar
21
clinvar
105
Total 63 61 56 266 23

Highest pathogenic variant AF is 0.0000460

Variants in CYP17A1

This is a list of pathogenic ClinVar variants found in the CYP17A1 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
10-102830536-G-GA Congenital adrenal hyperplasia Uncertain significance (Jun 14, 2016)298615
10-102830572-G-A Deficiency of steroid 17-alpha-monooxygenase Uncertain significance (Jan 12, 2018)298616
10-102830635-G-T Deficiency of steroid 17-alpha-monooxygenase Uncertain significance (Jan 13, 2018)298617
10-102830637-G-T Deficiency of steroid 17-alpha-monooxygenase Uncertain significance (Jan 13, 2018)298618
10-102830705-G-A Conflicting classifications of pathogenicity (Dec 05, 2023)595664
10-102830705-G-C Likely benign (Mar 19, 2022)2114156
10-102830708-G-A Likely benign (Mar 22, 2023)2848546
10-102830708-G-T Inborn genetic diseases Uncertain significance (Mar 20, 2023)2526756
10-102830714-C-G Uncertain significance (Aug 17, 2023)2841398
10-102830714-C-T Likely benign (Sep 28, 2019)1138128
10-102830716-C-T Uncertain significance (May 01, 2021)1486975
10-102830720-C-T Likely benign (Jan 25, 2024)1108405
10-102830726-T-C Likely benign (Apr 06, 2023)2852312
10-102830737-C-A Uncertain significance (Sep 24, 2021)2070243
10-102830741-G-A Deficiency of steroid 17-alpha-monooxygenase Conflicting classifications of pathogenicity (Oct 30, 2023)877968
10-102830742-C-T Deficiency of steroid 17-alpha-monooxygenase Likely pathogenic (May 09, 2023)2681111
10-102830743-G-A Deficiency of steroid 17-alpha-monooxygenase Pathogenic/Likely pathogenic (Dec 18, 2023)1524567
10-102830746-C-T Inborn genetic diseases Uncertain significance (Apr 28, 2022)2286525
10-102830750-G-T Likely benign (Oct 31, 2021)1615516
10-102830761-TGAAAGAGTC-T Deficiency of steroid 17-alpha-monooxygenase • 17-alpha-hydroxylase/17,20-lyase deficiency, combined complete Pathogenic (Mar 23, 2024)631622
10-102830771-G-A Deficiency of steroid 17-alpha-monooxygenase Likely benign (Dec 14, 2023)755651
10-102830776-G-A Likely benign (Oct 08, 2021)1608983
10-102830780-G-C Likely benign (Feb 15, 2021)1633786
10-102830786-C-T Likely benign (Oct 24, 2021)1612938
10-102830789-G-A Likely benign (Dec 20, 2022)1094826

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
CYP17A1protein_codingprotein_codingENST00000369887 87003
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.0002630.9851257090391257480.000155
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.242192770.7910.00001623337
Missense in Polyphen80107.320.745451292
Synonymous-0.01091141141.000.000007011002
Loss of Function2.16919.20.4689.92e-7226

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0001810.000181
Ashkenazi Jewish0.0001070.0000992
East Asian0.0005440.000544
Finnish0.00004620.0000462
European (Non-Finnish)0.0001440.000141
Middle Eastern0.0005440.000544
South Asian0.0002310.000229
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Conversion of pregnenolone and progesterone to their 17- alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty. {ECO:0000269|PubMed:22266943}.;
Disease
DISEASE: Adrenal hyperplasia 5 (AH5) [MIM:202110]: A form of congenital adrenal hyperplasia, a common recessive disease due to defective synthesis of cortisol. Congenital adrenal hyperplasia is characterized by androgen excess leading to ambiguous genitalia in affected females, rapid somatic growth during childhood in both sexes with premature closure of the epiphyses and short adult stature. Four clinical types: 'salt wasting' (SW, the most severe type), 'simple virilizing' (SV, less severely affected patients), with normal aldosterone biosynthesis, 'non-classic form' or late- onset (NC or LOAH) and 'cryptic' (asymptomatic). {ECO:0000269|PubMed:10720067, ECO:0000269|PubMed:11549685, ECO:0000269|PubMed:11836339, ECO:0000269|PubMed:12466376, ECO:0000269|PubMed:14671162, ECO:0000269|PubMed:1515452, ECO:0000269|PubMed:1714904, ECO:0000269|PubMed:1740503, ECO:0000269|PubMed:19793597, ECO:0000269|PubMed:24140098, ECO:0000269|PubMed:24498484, ECO:0000269|PubMed:25650406, ECO:0000269|PubMed:2808364, ECO:0000269|PubMed:8027220, ECO:0000269|PubMed:8245018, ECO:0000269|PubMed:8345056, ECO:0000269|PubMed:8396144, ECO:0000269|PubMed:8550762, ECO:0000269|Ref.20}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Cortisol synthesis and secretion - Homo sapiens (human);Cushing,s syndrome - Homo sapiens (human);Steroid hormone biosynthesis - Homo sapiens (human);Prolactin signaling pathway - Homo sapiens (human);Ovarian steroidogenesis - Homo sapiens (human);17-Beta Hydroxysteroid Dehydrogenase III Deficiency;Steroidogenesis;Apparent mineralocorticoid excess syndrome;3-Beta-Hydroxysteroid Dehydrogenase Deficiency;21-hydroxylase deficiency (CYP21);Corticosterone methyl oxidase I deficiency (CMO I);Corticosterone methyl oxidase II deficiency - CMO II;Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia due to 17 Alpha-hydroxylase Deficiency;Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia due to 21-hydroxylase Deficiency;Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;Androgen and Estrogen Metabolism;17-alpha-hydroxylase deficiency (CYP17);Aromatase deficiency;11-beta-hydroxylase deficiency (CYP11B1);Androgen Receptor Network in Prostate Cancer;Glucocorticoid and Mineralcorticoid Metabolism;Oxidation by Cytochrome P450;Steroid Biosynthesis;Metapathway biotransformation Phase I and II;Phase I - Functionalization of compounds;Metabolism of lipids;Endogenous sterols;Cytochrome P450 - arranged by substrate type;Biological oxidations;Metabolism;Androgen biosynthesis;Metabolism of steroid hormones;Metabolism of steroids;C21-steroid hormone biosynthesis and metabolism;Glucocorticoid biosynthesis;androgen biosynthesis;glucocorticoid biosynthesis;superpathway of steroid hormone biosynthesis;Steroid hormones (Consensus)

Recessive Scores

pRec
0.806

Intolerance Scores

loftool
0.455
rvis_EVS
-0.69
rvis_percentile_EVS
14.97

Haploinsufficiency Scores

pHI
0.0363
hipred
N
hipred_score
0.309
ghis
0.482

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
S
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.897

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Cyp17a1
Phenotype
skeleton phenotype; renal/urinary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan);

Gene ontology

Biological process
steroid biosynthetic process;androgen biosynthetic process;glucocorticoid biosynthetic process;sex differentiation;steroid metabolic process;sterol metabolic process;hormone biosynthetic process;progesterone metabolic process;oxidation-reduction process
Cellular component
endoplasmic reticulum;endoplasmic reticulum membrane;axon;neuronal cell body
Molecular function
steroid 17-alpha-monooxygenase activity;iron ion binding;oxygen binding;heme binding;17-alpha-hydroxyprogesterone aldolase activity